

PATENT Attorney Docket No. 056291-5296

THE UNITED STATES PATENT AND TRADEMARK OFFICE

| In re Application of: |) | | |
|---|-----------------------------|--|--|
| David Michael ANDREWS, et al. | Confirmation No.: 3394 | | |
| Application No.: 10/586,954 |) Group Art Unit: 1614 | | |
| Filed: July 25, 2006 | Examiner: Unassigned | | |
| For: IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION |) Date: April 20, 2007) | | |

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

<u>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</u>

UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants request the Examiner to consider this Supplemental Information Disclosure Statement and the documents listed on the attached Form PTO-1449. To the best of the undersigned's knowledge, this Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe a fee is due for filing this Supplemental Information Disclosure Statement.

With the exception of U.S. Patents and Publications, copies of the listed documents are attached. Applicants respectfully request that the Examiner initial and return the Form PTO-1449, indicating that the information has been considered and made of record herein.

ATTORNEY DOCKET NO.: 056291-5296

Application No.: 10/586,954

Page 2

This submission does not represent that a search has been made or that no better art exists and

does not constitute an admission that each or all of the listed documents are material or constitute

"prior art." Applicants reserve the right to take appropriate action to establish the patentability of the

disclosed invention over the listed documents, should one or more of the documents be applied against

the claims of the present application.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized

by this paper to charge any additional fees during the entire pendency of this application including fees

due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time

fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a

CONSTRUCTIVE PETITION FOR EXTENSION OF TIME in accordance with 37 C.F.R. §

1.136(a)(3).

Respectfully Submitted,

Morgan Lewis & Bocking

Date:

April 20, 2007

Morgan Lewis & Bockius LLP

Customer No. 09629

1111 Pennsylvania Avenue, N.W.

Washington, D.C. 20004 Tel. No.: 202-739-3000

By: Donald J. Bird

Registration No. 25,323

Tel. No.: (202) 739-5915

Fax No.: (202) 739-3001

Attorney Docket No. Application No.: INFORMATION DISCLOSURE CHATTON 056291-5296-US 10/586,954 (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 **U.S. PATENT DOCUMENTS** Initial Document No. Date Name Class Sub-Class Filing Date **A**1 US 4,983,608 January 8, 1991 Effland et al. A2 US 5,516,775 May 14, 1996 Zimmerman et al. A3 US 5,521,184 May 28, 1996 Zimmermann **A4** US 5,610,303 March 11, 1997 Kimura et al. **A5** US 5,739,143 April 14, 1998 Adams et al. **A6** US 5,859,041 January 12, 1999 Liverton et al. **A**7 US 6,835,726 December 28, 2004 Cushing et al. US 20030144303 July 31, 2003 Α8 Hawley et al. Α9 US 20060079543 April 13, 2006 Sum et al. A10 US 20030191307 October 9, 2003 Blumenkopf et al. FOREIGN PATENT DOCUMENTS Document No. Country Class Sub-Class Translation **B**1 CA 2231765 September 13, 1998 Canada EP 0135472 January 18, 1989 B2 **EPO** US 4,659,363 B3EP 0363002 June 22, 1994 **EPO B4** EP 0379806 April 10, 1996 **EPO B5** EP 0945443 August 13, 2003 EPO B6 July 23, 2003 EP 1056742 **EPO B**7 HU 220630 March 28, 2002 Hungary Claims **B**8 WO 91/18887 December 12, 1991 **WIPO B9** WO 92/20642 November 26, 1992 **WIPO** B10 WO 95/09847 April 13, 1995 WIPO WO 95/09851 B11 April 13, 1995 **WIPO B12** WO 95/09852 April 13, 1995 WIPO B13 WO 95/09853 April 13, 1995 **WIPO** B14 WO 95/15952 June 15, 1995 **WIPO** B15 WO 96/05177 February 22, 1996 **WIPO B16** WO 96/28427 September 19, 1996 WIPO B17 WO 96/40143 December 19, 1996 **WIPO** B18 WO 97/19065 May 29, 1997 WIPO B19 WO 97/35856 October 2, 1997 **WIPO B20** WO 97/40017 October 30, 1997 **WIPO** B21 WO 97/44326 November 27, 1997 **WIPO B22** WO 9747618 December 18, 1997 **WIPO** B23 WO 98/11095 March 19, 1998 WIPO **B24** WO 98/16230 April 23, 1998 WIPO **B25** May 7, 1998 WO 98/18782 WIPO **B26** WO 98/25619 June 18, 1998 WIPO **B27** WO 98/33798 August 6, 1998 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Date Considered Examiner

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No. Application No.: INFORMATION DISCLOSURE CONTROL 056291-5296-US 10/586,954 (Use several sheets if necessary) Applicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 **U.S. PATENT DOCUMENTS** Initial Document No. Date Name Class Sub-Class Filing Date FOREIGN PATENT DOCUMENTS Document No. Date Class **Country** Sub-Class Translation WO 98/41512 **B28** September 24, 1998 WIPO B29 WO 98/54093 December 3, 1998 WIPO **B30** WO 98/56788 December 17, 1998 WIPO **B31** WO 99/01136 Jan 14, 1999 WIPO **B32** WO 99/18096 April 22, 1999 WIPO WO 99/18942 **B33** April 22, 1999 WIPO **B34** WO 99/31073 June 24, 1999 WIPO US 6,432,963 **B35** WO 99/32121 July 1, 1999 **WIPO B36** WO 99/41253 August 19, 1999 WIPO **B37** WO 99/50250 October 7, 1999 WIPO WO 99/50251 **B38** October 7, 1999 WIPO B39 WO 00/12485 March 9, 2000 **WIPO** B40 WO 00/12486 March 9, 2000 **WIPO B41** WO 00/17202 March 30, 2000 WIPO B42 WO 00/17203 March 30, 2000 WIPO B43 WO 00/21926 April 20, 2000 WIPO **B44** WO 00/25780 May 11, 2000 WIPO **B45** WO 00/26209 May 11, 2000 WIPO B46 WO 00/39101 July 6, 2000 **WIPO** B47 WO 00/44750 August 3, 2000 **WIPO B48** WO 00/49018 August 24, 2000 **WIPO** B49 WO 00/53595 September 14, 2000 WIPO B50 WO 00/55161 September 21, 2000 WIPO B51 WO 00/59892 October 12, 2000 **WIPO** B52 WO 00/78731 December 28, 2000 WIPO B53 WO 01/14375 March 1, 2001 WIPO **B54** WO 01/29009 April 26, 2001 **WIPO** B55 WO 01/30778 May 3, 2001 **WIPO B56** WO 01/37835 May 31, 2001 **WIPO B57** WO 01/47897 July 5, 2001 **WIPO B58** WO 01/47921 July 5, 2001 WIPO **B59** WO 01/60816 August 23, 2001 WIPO B60 WO 01/64653 September 7, 2001 WIPO B61 WO 01/64654 September 7, 2001 **WIPO** OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Attorney Docket No. Application No.: INFORMATION DISCLOSURE CITATION 056291-5296-US 10/586,954 (Use several sheets if necessary) pplicants: ANDREWS et al. APR 2 0 2007 PTO Form 1449 Filing Date: July 25, 2006 Group Art Unit: 1614 April 20, 2007 PATENT DOCUMENTS Initial Document No. Date Name Class Sub-Class Filing Date FOREIGN PATENT DOCUMENTS Document No. Date Country Class Sub-Class Translation September 7, 2001 **B62** WO 01/64655 **WIPO B63** WO 01/64656 September 7, 2001 WIPO WO 01/72717 October 4, 2001 **B64 WIPO B65** WO 02/04429 January 17, 2002 WIPO **B**66 WO 02/65979 August 29, 2002 **WIPO B67** WO 02/66481 August 29, 2002 **WIPO B68** WO 02/92573 November 21, 2002 WIPO **B69** WO 02/96887 December 5, 2002 **WIPO B**70 WO 02/96888 December 5, 2002 **WIPO** US 20040224966 **B71** WO 03/007955 January 30, 2003 **WIPO** B72 WO 03/029249 April 10, 2003 WIPO **B73** WO 03/031446 April 17, 2003 WIPO WIPO B74 WO 03/076433 September 18, 2003 **B75** WO 03/076434 September 18, 2003 WIPO **B76** WO 03/076435 September 18, 2003 **WIPO B77** WO 03/076436 September 18, 2003 **WIPO B78** WO 04/005283 January 15, 2004 **WIPO** B79 May 27, 2004 WO 04/043467 WIPO **B80** WO 04/043953 May 27, 2004 WIPO October 14, 2004 B81 WO 04/087698 WIPO **B82** WO 04/087699 October 14, 2004 WIPO B83 WO 04/101549 November 25, 2004 WIPO B84 WO 04/101564 November 25, 2004 WIPO WIPO B85 WO 05/012298 February 10, 2005 **B86** WO 05/037800 April 28, 2005 **WIPO** B87 WO 05/075468 August 18, 2005 WIPO B88 WO 05/113550 December 1, 2005 **WIPO** Abstract B89 WO 05/116025 December 8, 2005 **WIPO** B90 WO 06/034872 April 6, 2006 **WIPO** B91 WO 06/050076 May 11, 2006 WIPO B92 WO 06/064251 June 22, 2006 WIPO **B93** WO 06/075152 July 20, 2006 WIPO **B94** WO 06/095159 September 14, 2006 WIPO Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIP E 2.8 APR 2.0 2007

| INFORMATION DISCLOSOR CITATION | | Attorney Docket No. 056291-5296-US | | | Application No.: 10/586,954 | | | | | | |
|--------------------------------|--|---|---|----------------------------|--------------------------------|--------------|----------------------|-----------------------|--|--|--|
| | (1 | Use several sheets if necess | ary) | Applicants: A | NDREWS et a | al. | | | | | |
| | PTO Form 1449 April 20, 2007 | | | Filing Date: July 25, 2006 | | | Group Art Unit: 1614 | | | | |
| | | | | TENT DOCUM | ENTS | | | | | | |
| Initial | - | Document No. | Date | N: | ame | Class | Sub-Class | Filing Date | | | |
| | | | EODEICN I | | THE STREET | | | | | | |
| | | Document No. | FOREIGN P Date | PATENT DOC | umENTS untry | Class | Sub-Class | Translation | | | |
| | | | | | 1111. 9 | U | Sub-Ciest | Handiation | | | |
| | | OTHER DOC | IIMENTS (Includi | ng Author Tit | la Data Perti | nant Pac | an oto) | | | | |
| | C1 | OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Blain, S. et al. "Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27 ^{Kip1} with cyclin A-Cdk2 and cyclin D2-Cdk4" The Journal of Biological Chemistry, 1997, Vol 272, No.41, pp 25863-25872. | | | | | | | | | |
| | C2 | Boschelli, D. et al. "Synthesis and tyrosine kinase inhibitory activity of a series of 2-amino-8H-pyrido[2,3-d]pyrimidines: identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors" J. Med. Chem., 1998, Vol 41, pp 4365-4377. | | | | | | | | | |
| | C3 | Deady L. et al. "Reactions | et al. "Reactions of some quinazoline compounds with ethoxymethylenemalonic acid derivatives" J. clic Chem., 1989, Vol 26, pp 161-168. | | | | | | | | |
| | C4 | El-Kerdawy, M. et al. "2,4-Bis(substituted)-5-nitropyrimidines of expected diuretic action" Egypt. J. Chem., 1986, 29, Vol 2, No. 2, pp 247-251. | | | | | | | | | |
| | C5 | Fiziol Akt Veshchestva, 1975, 7, pp 68-72. | | | | | | | | | |
| | C6 | Ghosh, D. et al. "2,4-Bis(arylamino)-5-methylpyrimidines as antimicrobial agents" J. Med. Chem., 1967, Vol 10, pp 974-975. | | | | | | | | | |
| l n | C7 | Ghosh, D., "2,4-Bis(arylamino)-6-methyl pyrimidines as antimicrobial agents" Chemical Abstracts, 1981, Vol 95, No.11, Columbus, Ohio, US; Abstract No. 97712f; pp 648; XP002109184 abstract & J. Indian Chem. Soc., 1981, Vol 58, No.5, pp 512-513, India. | | | | | | | | | |
| | | Schmidt, H. et al. "A conve 1987, Vol 24, pp 1305-130 | Schmidt, H. et al. "A convenient synthesis of 2-substituted 4-amino-5-pyrimidinecarbonitriles" J. Heterocyclic Chem., 1987, Vol 24, pp 1305-1307. | | | | | | | | |
| | | Simone, J. "Oncology: intr | roduction" Bennett, | J. Textbook of | Medicine, 20tl | h Edition, | Vol 1, 1996, | pp 1004-1010. | | | |
| | C10 | Volin, M. et al. "Cell cycle d594-601. | e implications in the | pathogenesis o | f rheumatoid a | arthritis" I | Frontiers in B | ioscience, 2000, 5, | | | |
| | | Zimmermann, J. et al. "Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC)" Arch. Pharm. Pharm. Med. Chem. 1996, 329 (7), pp 371-376. | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| xaminer | | | Date Cons | sidered | | | | | | | |
| xaminer: | Initial | if reference considered, wh | ether or not citation | is in conforma | nce with MPE | P 609; dr | aw line throug | gh citation if not in | | | |